Effects of cannabinoids on immune checkpoint inhibitor response: CCTG pooled analysis of individual patient data
Improved iPFS with cannabinoid use in patients treated with durvalumab plus tremelimumab ± chemotherapy did not translate into OS benefits. This study supports the safe use of cannabinoids in the context of combination ICI therapy.
Authors
- Pierre-Olivier Gaudreau (ORCID: https://orcid.org/0000-0003-3755-8836)
- Daniel J. Renouf (ORCID: https://orcid.org/0000-0002-7597-6089)
- Keyue Ding (ORCID: https://orcid.org/0000-0002-3496-6415)
- Rosalyn A. Juergens (ORCID: https://orcid.org/0000-0001-8627-4704)
- Desirée Hao (ORCID: https://orcid.org/0000-0003-1727-1205)
- Natasha B. Leighl (ORCID: https://orcid.org/0000-0002-3249-4602)
- Francisco Vera-Badillo (ORCID: https://orcid.org/0000-0003-1068-3258)
- Lesley Seymour (ORCID: https://orcid.org/0000-0001-8081-0799)
- Christopher O’Callaghan (ORCID: https://orcid.org/0000-0002-8633-2473)
- Dongsheng Tu (ORCID: https://orcid.org/0000-0003-4842-2184)
- Eric X. Chen (ORCID: https://orcid.org/0000-0002-4581-8848)
- Andrea S. Fung (ORCID: https://orcid.org/0000-0002-2031-6921)
- Courtney H. Coschi
- Justin Tong (ORCID: https://orcid.org/0000-0002-3991-7292)
Institutions
- University Health Network (CA)
- University of Calgary (CA)
- Canadian Partnership Against Cancer (CA)
- Princess Margaret Cancer Centre (CA)
- Health Net (US)
- Kingston Health Sciences Centre (CA)
- Pancreas Centre (Canada) (CA)
- McMaster University (CA)
Publication Details
- Journal
- Immunotherapy
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1080/1750743x.2025.2485012
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Canadian Cancer Society Research Institute